All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Roundtable discussion—Multiple Myeloma Hub Satellite Symposium: Should 'cure' be the goal for MM?
Bookmark this article
During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma?
Roundtable discussion—Multiple Myeloma Hub Satellite Symposium: Should 'cure' be the goal for MM?
This video captures the roundtable discussion with Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University (Paris, FR), María-Victoria Mateos, University Hospital of Salamanca (Salamanca, ES), and Sagar Lonial, Winship Cancer Institute of Emory University (Atlanta, US), and includes the concluding remarks of the Satellite Symposium as a whole.
Questions that were answered include:
Do we think that the cure vs chronic disease model may be differentially applicable based on genetics? (00:16)
What do you define as acceptable safety profiles for smoldering multiple myeloma (SMM), and where do you set the bar? (04:42)
Does it make a difference to treat SMM patients earlier rather than wait for them to develop IMWG-defined progression? (09:48)
Does immune status/immune function impact the ability to ultimately cure subsets of patients? (13:44)
What do you think of Sagar Lonial's 'siren song' of MRD response? (17:55)
Comment on the curative potential of allogeneic transplant (21:07)
Can you wake the immune senescence with interferon? (22:50)
Final remarks by Sagar Lonial (24:30)
Should 'cure' be the goal for multiple myeloma?
Multiple Myeloma Hub Satellite Symposium: Summary and conclusions
Sagar Lonial's summary and conclusion slides from the first Multiple Myeloma Hub Satellite Symposium are available as a downloadable resource below.
Download the slides here!Find below links to the talks from the symposium:
'Does 'cure' have a different meaning in MM?' presented by Mohamad Mohty.
'Is the treatment of high-risk smoldering multiple myeloma (SMM) the way for achieving the cure?' presented by María-Victoria Mateos.
'Is transplantation still relevant? If yes, in which context?' presented by Sagar Lonial.
'Treating elderly and frail patients with MM: Cure versus disease control' presented by Vincent Rajkumar.
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox